LAVA Therapeutics N.V. (LVTX)

LAVA Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	11.98	6.77	19.39	5.35	3.75
Revenue Growth (YoY)	77.01%	-65.09%	262.45%	42.78%	-
Cost of Revenue	24.55	36.04	-	-	15.7
Gross Profit	-12.57	-29.27	19.39	5.35	-11.95
Selling, General & Admin	13.23	14.12	14.12	12.02	2.72
Research & Development	-	-	40.11	36.95	-
Operating Expenses	13.23	14.12	54.23	48.96	2.72
Operating Income	-25.79	-43.39	-34.84	-43.61	-14.67
Interest Expense	-0.52	-0.47	-	-0.63	-0.34
Interest & Investment Income	3.76	3.67	0.26	-	-
Currency Exchange Gain (Loss)	1.97	-1.42	2.92	2.04	-0.87
EBT Excluding Unusual Items	-20.58	-41.61	-31.66	-42.2	-15.88
Merger & Restructuring Charges	-3.9	-	-	-	-
Pretax Income	-24.48	-41.61	-31.66	-42.2	-15.88
Income Tax Expense	0.63	0.26	0.25	0.16	0.04
Net Income	-25.11	-41.87	-31.91	-42.36	-15.93
Net Income to Common	-25.11	-41.87	-31.91	-42.36	-15.93
Shares Outstanding (Basic)	27	27	26	20	0
Shares Outstanding (Diluted)	27	27	26	20	0
Shares Change (YoY)	0.38%	3.12%	31.21%	4850.36%	-10.81%
EPS (Basic)	-0.94	-1.57	-1.23	-2.14	-39.90
EPS (Diluted)	-0.94	-1.57	-1.23	-2.14	-39.90
Free Cash Flow	-19.57	-41.01	3.46	-29.41	-9.81
Free Cash Flow Per Share	-0.73	-1.53	0.13	-1.49	-24.58
Gross Margin	-104.89%	-	100.00%	100.00%	-
Operating Margin	-215.26%	-641.07%	-179.66%	-815.20%	-391.59%
Profit Margin	-209.60%	-618.57%	-164.55%	-791.68%	-425.06%
Free Cash Flow Margin	-163.30%	-605.91%	17.82%	-549.74%	-261.78%
EBITDA	-25.33	-42.78	-34.33	-43.28	-14.46
EBITDA Margin	-211.37%	-	-177.06%	-	-
D&A For EBITDA	0.47	0.61	0.5	0.33	0.21
EBIT	-25.79	-43.39	-34.84	-43.61	-14.67
EBIT Margin	-215.26%	-	-179.66%	-	-
Revenue as Reported	11.98	6.77	-	-	3.75

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q